Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eva Gaarsdal

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Ugeskrift for Laeger|November 21, 2009
[Stem cell harvesting after plerixafor treatment]Per Boye Hansen, Eva Gaarsdal
Ugeskrift for Laeger|November 6, 2009
[Mobilisation of haematopoietic stem cells with plerixafor--secondary publication]Per Boye Hansen, Eva Gaarsdal
Experimental Hematology|February 2, 2002
Efficacy and safety of CD34-selected and CD19-depleted autografting in multiple myeloma patients: a pilot studyThomas Rasmussen, Bosse Björkstrand, Heidi Andersen, et al.
Cancer Immunology, Immunotherapy : CII|February 27, 2004
Vaccination with p53-peptide-pulsed dendritic cells, of patients with advanced breast cancer: report from a phase I studyInge Marie Svane, Anders E Pedersen, Hans E Johnsen, et al.
Cancer Immunology, Immunotherapy : CII|February 8, 2007
Vaccination with p53 peptide-pulsed dendritic cells is associated with disease stabilization in patients with p53 expressing advanced breast cancer; monitoring of serum YKL-40 and IL-6 as response biomarkersInge Marie Svane, Anders E Pedersen, Julia S Johansen, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Ugeskrift for Laeger|November 21, 2009
[Stem cell harvesting after plerixafor treatment]Per Boye Hansen, Eva Gaarsdal
Ugeskrift for Laeger|November 6, 2009
[Mobilisation of haematopoietic stem cells with plerixafor--secondary publication]Per Boye Hansen, Eva Gaarsdal
Experimental Hematology|February 2, 2002
Efficacy and safety of CD34-selected and CD19-depleted autografting in multiple myeloma patients: a pilot studyThomas Rasmussen, Bosse Björkstrand, Heidi Andersen, et al.
Cancer Immunology, Immunotherapy : CII|February 27, 2004
Vaccination with p53-peptide-pulsed dendritic cells, of patients with advanced breast cancer: report from a phase I studyInge Marie Svane, Anders E Pedersen, Hans E Johnsen, et al.
Cancer Immunology, Immunotherapy : CII|February 8, 2007
Vaccination with p53 peptide-pulsed dendritic cells is associated with disease stabilization in patients with p53 expressing advanced breast cancer; monitoring of serum YKL-40 and IL-6 as response biomarkersInge Marie Svane, Anders E Pedersen, Julia S Johansen, et al.
Pageof 1